

Significant Questions Remain for H.R. 3

April 22, 2021, Washington, DC – Today, members of the House Committee on Energy and Commerce re-introduced H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. While MANA commends the intent to lower drug costs and out of pocket expenditures for consumers, significant questions regarding the methodology remain. We continue to focus on equity in the healthcare space and the utilization of a Quality Adjusted Life Years (QALY) measurement, and other foreign reference pricing models could negatively impact under-served communities, who are often in most need of pricing relief.

MANA President and CEO, Amy Hinojosa, said, “Pricing models simply have not historically accounted properly for our poorest, under-served communities. The specific financial needs of these communities require a more granular level of understanding for their capacity to pay for life-saving medications. We hope the bill sponsors can clarify the questions surrounding pricing models and the impact on those who need pricing relief the most.”